A Phase 2, Open-label, Multicenter Study of the Safety and Efficacy of TAK-007 in Adult Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma


NCT Number:



Study Status:






TAK-007 is being developed as a possible treatment for Lymphoma. TAK-007 is a cell therapy, which means that it consists of live cells that have been modified to help your body to fight Lymphoma. The use of TAK-007 in this study is experimental. Fresh (unfrozen) CAR NK cells, similar to TAK-007, are being tested in another study. In this study, frozen TAK-007 cell therapy will be used for the first time in humans. This means that at present there is less information available regarding the safety and ability to treat cancer with this medication in humans. The main purpose of this study is to: -Test the safety of TAK-007 - See how TAK-007 is tolerated by subjects - Understand how well TAK-007 works as treatment for Lymphoma

Are you Eligible? (Inclusion Criteria)

  • Do you have relapsed or refractory B-cell non-Hodgkin lymphoma, large B-cell
  • lymphoma, or indolent non-Hodkins lymphoma?
  • Have you previously received 2 lines of systemic therapy?
  • Are you 18 years of age or older?
  • Are you not pregnant?

Specialty Area(s)

Lymphoma, Immunotherapy

Principal Investigator

Profile Headshot
  • Director, Translational Research, Blood and Marrow Transplantation
  • Clinical Lead, CAR-T Cell Program

Trial Location(s)

CUIMC/Herbert Irving Pavilion
161 Fort Washington Avenue
New York, NY 10032